Jacobson Pharma Corporation (2633) Stock Overview

Jacobson Pharma Corporation Limited, through its subsidiaries, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including the respiratory, cardiovascular, central nervous system, gastrointestinal, genito-urinary, musculoskeletal, endocrine and metabolic, dermatological, anti-allergics, scar treatment, oral anti-diabetics, and anti-infective, as well as arsenic trioxide oral solutions. It also provides branded medicines; health and wellness products; and proprietary Chinese medicines, such as Po Chai pills, Ho Chai Kung, and Shiling oil, as well as Contractubex, Smartfish, Rowatanal, Oncotype DX, and AIM Atropine products. In addition, it engages in the trading of medical supplies; procurement of packaging materials; treasury services; sale of healthcare and herbal products; research and development; and property holding activities. Jacobson Pharma Corporation Limited sells its products to hospitals and clinics, and registered pharmacies, as well as to doctors in private and retail outlets, and trading companies. The company was incorporated in 2016 and is headquartered in Kwun Tong, Hong Kong. Jacobson Pharma Corporation Limited is a subsidiary of Kingshill Development Limited.